Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
To tested if the adding of consolidative SBRT to TKI in EGFR mutated patients with less than or equal to 5 metastatic sites (primary + 5) will improve progression free survival (PFS) compared to TKI alone.
详细描述
This protocol is a randomized phase III trial of TKI versus consolidative Stereotactic Body Radiation Therapy (SBRT) plus TKI for patients with Stage IV non-small cell lung cancer (NSCLC).
Prior to accrual on the trial, patients with Stage IV NSCLC will be tested with positive EGFR mutation. Patients who with fewer than or equal to 5 sites of oligometastatic disease will be randomized toTKI or consolidative SBRT to all sites of disease (followed by TKI at the medical oncologist's discretion). Choices of TKI will be determined by the medical oncologist based on clinical appropriateness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed metastatic lung adenocarcinoma (recurrent or de novo) harboring sensitizing EGFR mutations (L858R, exon 19 deletion, G719A, L861Q, S768I, exon 19 insertions) with oligometastatic disease (≤5 discrete lesions of disease irrespective of location, inclusive of the primary lesion):
- •all sites of disease must be amenable to definitive treatment with a local therapy (surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy) as determined by surgery, interventional radiology and radiation oncology
- •all intrathoracic lymph nodes (including hilar, mediastinal, and supraclavicular nodal disease) are considered 1 discrete lesion.
- •No brain metastasis is allowed.
- •Patients already started on erlotinib are eligible as long as their sites of disease are determined to be eligible for definitive local therapy by consensus of the principal investigators within 12 weeks of the patient first taking erlotinib.
- •Lung adenocarcinoma histology confirmed
- •Karnofsky Performance Status ≥ 70%
- •Adequate bone marrow, liver and renal function, as specified below:
- •Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
- •Hemoglobin ≥ 8 g/dL
- •Platelets ≥ 100 x 109/L
- •Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)
- •AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present
- •Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
- •For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
- •Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter
排除标准
- •Treatment with TKI prior to developing metastatic disease
- •Malignant pleural effusion or pleural disease
- •Leptomeningeal disease or brain metastasis.
- •Any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy
- •Women who are breastfeeding or pregnant
- •Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment.
- •Any medical co-morbidities that would preclude surgery or radiation therapy
研究组 & 干预措施
TKI without SBRT
Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.
The oligometastatic disease will not receive SBRT
干预措施: TKI (Gefitinib or Tarceva ) (Drug)
TKI with SBRT
experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.
SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions.
干预措施: TKI (Gefitinib or Tarceva ) (Drug)
结局指标
主要结局
Progression free survival
时间窗: 4 years
Evaluate the effect of TKI with or without SBRT on progression free survival,to describe local control and out-of-field disease progression
次要结局
- Overall survival(4 years)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])(4 years)
研究者
ming zeng, MD
Director of Cancer Center
Sichuan Provincial People's Hospital